Ralph V. Boccia

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Dirix, István Takács, Guy Jérusalem et al. · Breast Cancer Research and Treatment · 2017 · 756 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

David J. Kuter, Mathias Rummel, Ralph V. Boccia et al. · New England Journal of Medicine · 2010 · 423 citations · Full text

Medicine, Hematology, Pharmacology +9

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

Adrian S. Dobs, Ralph V. Boccia, C. Croot et al. · The Lancet Oncology · 2013 · 383 citations

Medicine, Oncology, Pharmacotherapy +11